Dissemination of the Cardiovascular Risk Service
CVRSLive
1 other identifier
interventional
542
1 country
14
Brief Summary
The objective of this study is to evaluate the implementation of of a remote, pharmacist-led cardiovascular risk service (CVRS) in 12 large, organizationally and culturally diverse hospitals and health-systems, many with high proportions of minority and underserved patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable hypertension
Started Sep 2018
Longer than P75 for not_applicable hypertension
14 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 20, 2018
CompletedFirst Posted
Study publicly available on registry
September 6, 2018
CompletedStudy Start
First participant enrolled
September 27, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2024
CompletedAugust 13, 2024
August 1, 2024
4.8 years
August 20, 2018
August 12, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Factors influencing intervention implementation fidelity
Themes will be identified through interviews with key individuals involved in implementation of study intervention. Data from interviews will be analyzed using ATLAS ti to determine frequency and density of themes identified in interviews.
12 months following the start of the intervention at each site
Effect of physician/pharmacist collaboration on implementation fidelity
Development of implementation fidelity measures and adherence to fidelity measures
12 months following the start of the intervention at each site
Secondary Outcomes (4)
Adherence to guidelines for primary and secondary prevention of cardiovascular disease
12 months after the start of the intervention for each subject
Reach and adoption of intervention
12 months following the start of the intervention at each site
Development of payment contracts
36 months following the start of recruitment
Development of payment contracts
36 months following the start of recruitment
Study Arms (2)
CVRS Early Intervention
EXPERIMENTALPatients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.
CVRS Delayed Intervention
OTHERPatients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.
Interventions
1. Evaluate gaps in therapy 2. Contact patients regularly by email, phone and/or text message 3. Assess and counsel for medication adherence, side effects, life-style behaviors 4. Develop an action plan and send recommendations to provider
Eligibility Criteria
You may qualify if:
- Patient Subjects:
- English or Spanish speaking
- Seen in the clinic at least once in the previous 12 months
- Currently has one of the following diseases:
- Diabetes with HA1c 9.0% or greater and/or
- Hypertension (uncomplicated) with systolic blood pressure 150 mm Hg or greater
You may not qualify if:
- Inability to give consent
- Nursing home residence
- No telephone
- Cancer with a life expectancy less than 24 months
- Pregnancy
- Diagnosis of dementia
- Plans to terminate care from the clinic within 24 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Korey Kenneltylead
Study Sites (14)
Idaho State University
Pocatello, Idaho, 83201, United States
University of Illinois at Chicago: Mile Square Health Center
Chicago, Illinois, 60608, United States
Carle Foundation Hospital
Mahomet, Illinois, 61853, United States
Carle Foundation Hospital
Rantoul, Illinois, 61866, United States
Genesis Family Medical Center
Davenport, Iowa, 52804, United States
University of Iowa
Iowa City, Iowa, 52242, United States
UIHC River Crossing
Riverside, Iowa, 52327, United States
Siouxland Family Medicine Center
Sioux City, Iowa, 51104, United States
Northeast Iowa Family Practice Center
Waterloo, Iowa, 50702, United States
Henry Ford Health System: Harbortown
Detroit, Michigan, 48207, United States
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
Temple University
Philadelphia, Pennsylvania, 19140, United States
Texas Tech University Health Science Center
Amarillo, Texas, 79106, United States
Community Health Center of Snohomish County
Everett, Washington, 98203, United States
Related Publications (1)
Kennelty KA, Engblom NJ, Carter BL, Hollingworth L, Levy BT, Finkelstein RJ, Parker CP, Xu Y, Jackson KL, Dawson JD, Dorsey KK. Dissemination of a telehealth cardiovascular risk service: The CVRS live protocol. Contemp Clin Trials. 2021 Mar;102:106282. doi: 10.1016/j.cct.2021.106282. Epub 2021 Jan 12.
PMID: 33444781DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Korey Kennelty, PharmD
University of Iowa
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 20, 2018
First Posted
September 6, 2018
Study Start
September 27, 2018
Primary Completion
June 30, 2023
Study Completion
December 30, 2024
Last Updated
August 13, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- 12 months following the start of the study intervention.
1. Provide de-identified SAS datasets in transport format with the protocol, data dictionaries user manual . A data sharing agreement will be required. 2. Share data with all participating sites and place study links and information on PBRN website136 3. Present results to other PBRNs through AHRQ meetings. 4. Post the development and results on the .213 PRagmatic-Explanatory Continuum Indicator Summary